MEDICALPulmonaryHealth Calculator
🏥

C U R B65

Young patient with mild CAP, suitable for outpatient treatment

Understanding C U R B65Use the calculator below to check your health metrics

Why This Health Metric Matters

Why: This calculation helps assess important health parameters for clinical and personal wellness tracking.

How: Enter your values above and the calculator will apply validated formulas to compute your results.

  • Evidence-based calculations
  • Used in clinical settings worldwide
  • Regular monitoring recommended

Clinical Sample Scenarios

Low Risk - Young Adult

Low Risk

Young patient with mild CAP, suitable for outpatient treatment

Low Risk - Elderly Alert

Low Risk

Elderly patient but otherwise low risk

Moderate Risk (CURB-65 = 2)

Moderate

Elderly with elevated BUN and tachypnea

High Risk (CURB-65 = 3)

High Risk

Confused elderly patient with hypotension

Very High Risk (CURB-65 = 4-5)

Critical

Severe CAP requiring ICU consideration

Immunocompromised Patient

Special

Lower threshold for admission

Multilobar Pneumonia

Moderate

More extensive disease warrants admission

Urea in mmol/L

Moderate

Using international units for urea

Enter Patient Data

CURB-65 Criteria

Additional Parameters

Risk Factors

⚠️For informational purposes only — not medical advice. Consult a healthcare professional before acting on results.

🏥 Health Facts

— WHO

— CDC

What is the CURB-65 Score?

CURB-65 is a clinical prediction rule validated for predicting mortality in community-acquired pneumonia (CAP). It helps determine the most appropriate care setting: outpatient treatment, hospital admission, or ICU care.

The score was developed by the British Thoracic Society and is endorsed by the Infectious Diseases Society of America (IDSA) and American Thoracic Society (ATS) guidelines.

Clinical Pearl: CURB-65 is best at identifying LOW-RISK patients safe for outpatient treatment.

C

Confusion

U

Urea

R

RR≥30

B

BP Low

65

Age≥65

Score 0-1

Outpatient

Score 2

Observe/Admit

Score 3-5

Hospital/ICU

30-Day Mortality by CURB-65 Score

ScoreMortalityRiskDisposition
00.6-1.2%Low riskOutpatient
12.0-3.2%Low riskOutpatient or Brief Observation
25.2-9.0%Intermediate riskShort inpatient or Supervised Outpatient
312-17%High riskHospital admission
423-35%High riskHospital admission, consider ICU
540-60%Very high riskICU admission

Understanding CURB-65 Scoring

CURB-65 is a clinical prediction rule validated for assessing severity of community-acquired pneumonia (CAP) and guiding disposition decisions.

C

Confusion

New disorientation

U

Urea/BUN

>7 mmol/L (20 mg/dL)

R

Respiratory Rate

≥30/min

B

Blood Pressure

SBP <90 or DBP ≤60

65

Age

≥65 years

Risk Stratification and Mortality

Low Risk (Score 0-1)

0.6-2.7%

30-day mortality

Outpatient treatment appropriate

Intermediate Risk (Score 2)

6.8-9.2%

30-day mortality

Consider short hospitalization

High Risk (Score 3-5)

14-27%

30-day mortality

Hospital/ICU admission required

CRB-65 vs CURB-65

CURB-65 (Hospital Setting)

  • • Requires BUN laboratory test
  • • More accurate risk stratification
  • • Standard for inpatient decision-making
  • • Score 0-5 points

CRB-65 (Community/Primary Care)

  • • No laboratory tests needed
  • • Can be used at bedside/office
  • • Useful for initial triage
  • • Score 0-4 points

CAP Antibiotic Guidelines (IDSA/ATS 2019)

Outpatient (CURB-65 0-1)

  • No comorbidities: Amoxicillin OR Doxycycline OR Macrolide (if local resistance <25%)
  • With comorbidities: Amoxicillin-clavulanate OR Cephalosporin PLUS Macrolide/Doxycycline
  • Alternative: Respiratory fluoroquinolone (moxifloxacin, levofloxacin)

Non-ICU Inpatient (CURB-65 2-3)

  • • Beta-lactam (ceftriaxone, ampicillin-sulbactam, cefotaxime) PLUS Macrolide
  • • OR Respiratory fluoroquinolone monotherapy
  • • Duration: Minimum 5 days, until afebrile 48-72h and clinically stable

ICU Inpatient (CURB-65 4-5)

  • • Beta-lactam PLUS Macrolide (preferred)
  • • OR Beta-lactam PLUS Fluoroquinolone
  • • Add MRSA coverage if risk factors (vancomycin or linezolid)
  • • Add Pseudomonas coverage if risk factors (piperacillin-tazobactam, cefepime)

Clinical Pearls for CURB-65

  • 💡CURB-65 should be used in conjunction with clinical judgment, not in isolation
  • 💡Consider admission for score of 2 if other risk factors present (hypoxia, multilobar disease)
  • 💡Score of 3+ generally warrants ICU evaluation
  • 💡Young patients may have low CURB-65 despite severe illness
  • 💡Use PSI/PORT score if more detailed prognostication needed
  • 💡Social factors may necessitate admission even with low scores
  • 💡Always check oxygen saturation - not captured in CURB-65

ICU Admission Criteria (IDSA/ATS)

Major Criteria (1 = ICU)

  • • Septic shock requiring vasopressors
  • • Respiratory failure requiring mechanical ventilation

Minor Criteria (3+ = ICU)

  • • RR ≥30 breaths/min
  • • P/F ratio ≤250
  • • Multilobar infiltrates
  • • Confusion/disorientation
  • • BUN ≥20 mg/dL
  • • WBC <4,000 cells/μL
  • • Platelets <100,000/μL
  • • Temperature <36°C
  • • Hypotension requiring fluids

Common CAP Pathogens

Typical Bacteria

  • Streptococcus pneumoniae - Most common
  • • Haemophilus influenzae
  • • Moraxella catarrhalis
  • • Staphylococcus aureus (including MRSA)
  • • Gram-negative bacilli (elderly, comorbidities)

Atypical Pathogens

  • • Mycoplasma pneumoniae
  • • Chlamydophila pneumoniae
  • • Legionella pneumophila
  • • Respiratory viruses (influenza, RSV, SARS-CoV-2)

Factors Beyond CURB-65 for Admission Decision

  • Hypoxemia: SpO2 <90% or PaO2 <60 mmHg on room air
  • Multilobar involvement: Infiltrates in multiple lobes
  • Pleural effusion: Especially if large or loculated
  • Comorbidities: COPD, heart failure, diabetes, renal/liver disease, malignancy
  • Immunocompromise: HIV, transplant, chemotherapy, steroids
  • Social factors: Inability to take oral medications, no caregiver, homeless
  • Recent antibiotic failure: Treatment failure as outpatient
  • Rapid deterioration: Clinical worsening over hours

Antibiotic Duration Guidelines

Standard Duration

  • • Minimum 5 days of therapy
  • • Continue until afebrile for 48-72 hours
  • • Patient should be clinically stable
  • • No more than 1 CAP-associated sign of instability

Extended Duration Needed

  • • Legionella: 7-14 days
  • • Lung abscess: 4-6 weeks
  • • Empyema: 2-4 weeks + drainage
  • • Pseudomonas: 14 days
  • • MRSA: 7-21 days depending on severity

CURB-65 Quick Summary

Score 0-1

Outpatient

Mortality <3%

Score 2

Consider Admission

Mortality ~9%

Score 3-5

Hospital/ICU

Mortality 14-27%

Recognizing Treatment Failure

Early Failure (<72 hours)

  • • Persistent fever despite antibiotics
  • • Worsening respiratory status
  • • Hemodynamic instability
  • • Consider: resistant pathogen, wrong diagnosis, empyema

Late Failure (>72 hours)

  • • Initial improvement then deterioration
  • • Development of complications
  • • Consider: superinfection, empyema, drug fever
  • • May need additional imaging/cultures

Pneumonia Prevention

Vaccinations

  • • Pneumococcal vaccine (PCV20, PPSV23)
  • • Annual influenza vaccine
  • • COVID-19 vaccination
  • • Consider RSV vaccine (≥60 years)

Risk Reduction

  • • Smoking cessation
  • • Limit alcohol intake
  • • Good oral hygiene
  • • Manage comorbidities (diabetes, COPD, CHF)

Hospital Discharge Criteria

  • • Temperature ≤37.8°C (100°F) for ≥24 hours
  • • Heart rate ≤100 bpm
  • • Respiratory rate ≤24/min
  • • Systolic BP ≥90 mmHg without vasopressors
  • • SpO2 ≥90% on room air (or baseline O2)
  • • Able to maintain oral intake
  • • Mental status at baseline
  • • No other active medical issues requiring hospitalization

Follow-Up Recommendations

Clinical Follow-Up

  • • Phone call within 48-72 hours post-discharge
  • • Office visit within 1-2 weeks
  • • Assess symptom resolution
  • • Verify completion of antibiotics

Chest X-Ray Follow-Up

  • • Not routine for all patients
  • • Consider at 6-8 weeks if: smoker, age >50, persistent symptoms
  • • Rule out underlying malignancy
  • • Radiographic resolution may lag behind clinical

CURB-65 Limitations

  • Does not include oxygen saturation - critically important parameter
  • • May underestimate severity in young patients without comorbidities
  • • Does not account for comorbidities directly
  • • Social factors not considered
  • • Does not predict causative organism
  • • Originally validated in hospitalized patients
  • • Should supplement, not replace, clinical judgment

Special Populations

Elderly Patients

  • • May present atypically (falls, confusion, no fever)
  • • Higher mortality at all CURB-65 scores
  • • Consider aspiration pneumonia
  • • Assess functional status and goals of care

Immunocompromised

  • • Broader differential (PJP, CMV, Aspergillus)
  • • Lower threshold for admission
  • • May need empiric coverage for opportunistic infections
  • • Consider early bronchoscopy

COPD Patients

  • • Distinguish from acute exacerbation
  • • Cover for H. influenzae, M. catarrhalis
  • • Consider Pseudomonas if severe COPD or recent hospitalization
  • • Optimize bronchodilators and steroids

Healthcare-Associated

  • • Recent hospitalization/nursing home
  • • Broader antibiotic coverage needed
  • • Consider MRSA and Pseudomonas
  • • May need de-escalation after cultures

CAP Complications to Monitor

Pulmonary Complications

  • • Parapneumonic effusion/empyema
  • • Lung abscess
  • • ARDS
  • • Respiratory failure
  • • Necrotizing pneumonia

Systemic Complications

  • • Sepsis and septic shock
  • • Acute kidney injury
  • • Cardiac events (MI, arrhythmias)
  • • Multi-organ dysfunction
  • • Venous thromboembolism

Related Scoring Systems

  • CURB-65: C + U + R + B + 65 (0-5 points)
  • CRB-65: C + R + B + 65 (0-4 points, no BUN)
  • PSI/PORT: More detailed 20-variable score
  • SMART-COP: Predicts need for intensive respiratory support
  • A-DROP: Japanese modification of CURB-65

Recommended Diagnostic Workup

All Patients

  • • Chest X-ray
  • • Pulse oximetry
  • • CBC, BMP
  • • Blood cultures (inpatient)

Severe CAP

  • • Sputum culture and Gram stain
  • • Legionella and pneumococcal urinary antigens
  • • Procalcitonin (if available)
  • • ABG if hypoxic

Selected Patients

  • • CT chest (if CXR unclear)
  • • Respiratory viral panel
  • • COVID-19 testing
  • • Thoracentesis if effusion

Clinical Scenario Examples

45-year-old, alert, RR 22, BP 130/80, BUN 12 mg/dL

Score: 0 - Outpatient treatment appropriate

68-year-old, alert, RR 32, BP 115/70, BUN 24 mg/dL

Score: 3 (Age + RR + BUN) - Admit to hospital

72-year-old, confused, RR 34, BP 85/55, BUN 32 mg/dL

Score: 5 - ICU admission, consider severe CAP protocol

30-Day Mortality by CURB-65 Score

0

0.6%

1

2.7%

2

6.8%

3

14%

4

27%

5

57%

Need Personalized Pneumonia Assessment?

Get AI-powered analysis and treatment recommendations.

👈 START HERE
⬅️Jump in and explore the concept!
AI